PB) and animal-based (AB) proteins contain phosphorus, the presence of phytate in plant sources may offer a unique advantage by reducing intestinal absorption of this mineral.Limited evidence exists on whether PB protein, compared to AB protein, can better control phosphate levels among this population.Methods: This randomized, controlled, cross-over trial enrolled MHD patients with chronic hyperphosphatemia.Participants were randomly assigned to consume either PB or AB protein for 2 weeks, with a 2week washout between interventions.Serum phosphate, electrolytes, pre-albumin, dietary intake, and muscle mass were assessed through the study.The main outcome was mean change in serum phosphate level.Results: Total of 201 patients were screened, of whom 12 MHD patients were enrolled in the studied.Both groups consumed similar protein intake (1.24 vs. 1.15 g/kg/day, P=0.185), but the PB group had significantly higher phosphate intake (920 vs. 621 mg/day, P<0.001).At the end of the study, a significantly lower proportion of patients in the PB group had serum phosphate levels below 5 mg/ dL, which is considered optimal for this population (50% vs. 8.3%, P=0.025).Additionally, the mean change in serum phosphate level was significantly lower in the PB group compared to the AB group (-1.341.8 vs. -0.241.32mg/dL, P=0.041).No significant differences in the mean change of electrolytes, prealbumin, and muscle mass were observed between groups. Conclusion:In conclusions, this study suggests that PB protein consumption may be a promising strategy for managing hyperphosphatemia in dialysis patients without compromising other aspects of health.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Arimura et al. (Wed,) studied this question.